Michael B. Steinberg
Research Subjects
Michael B. Steinberg has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Amy C. Schmelzer
6 shared publicationsCristine D. Delnevo
From Rutgers–Robert Wood Johnson Medical School and the School of Public Health, New Brunswick, New Jersey
6 shared publications- Jonathan Foulds
Affiliations Department of Public Health Sciences, Penn State Center for Research on Tobacco and Health, Pennsylvania State University College of Medicine, Hershey Medical Center, Hershey, Pennsylvania, United States of America, Department of Psychiatry and Behavioral Health, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States of America
6 shared publications Donna L. Richardson
4 shared publicationsJeffrey L. Carson
3 shared publications- Michelle T. Bover Manderski
Department of Biostatistics & Epidemiology, Rutgers School of Public Health, Piscataway, NJ, United States
3 shared publications
Latest Publications
- 15 October 2013
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 159 (8) , 558-559
Increasing the “Smoking Age”: The Right Thing to Do
A critical aspect of tobacco control is to prevent young people from ever becoming smokers. Toward this aim, New York City has proposed to increase the legal age of sale for tobacco products from 1...
- 15 October 2013
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 159 (8) , 558-559
Increasing the “Smoking Age”: The Right Thing to Do
A critical aspect of tobacco control is to prevent young people from ever becoming smokers. Toward this aim, New York City has proposed to increase the legal age of sale for tobacco products from 1...
- 1 December 2011
- Published by Elsevier in Preventive Medicine
- Vol. 53 (6) , 433-434
Physicians' perceptions regarding effectiveness of tobacco cessation medications: Are they aligned with the evidence?
- 1 December 2011
- Published by Elsevier in Preventive Medicine
- Vol. 53 (6) , 433-434
Physicians' perceptions regarding effectiveness of tobacco cessation medications: Are they aligned with the evidence?
- 1 December 2011
- Published by Cambridge University Press (CUP) in Journal of Smoking Cessation
- Vol. 6 (2) , 85-88
Evaluation of Graphic Cigarette Warning Images on Cravings to Smoke
While health warnings are present on cigarette packs around the world, the nature of the warnings varies considerably between countries. In the United States, a small text warning citing the dangers of cigarette smoking is found on the side of all packs. This pilot study sought to determine whether graphic cigarette warning images, like those found in the United Kingdom and Canada, were better at decreasing cravings to smoke than existing text warnings found on cigarette packs in the United States. Twenty-five smokers seeking treatment to quit at a specialty tobacco treatment program were administered the Brief Questionnaire of Smoking Urges (QSU — BRIEF), a validated measure of craving, prior to and following exposure to cigarette pack warning images. The graphic cigarette warning images reduced cravings to smoke (6.20 point decrease) more than neutral images (3.36 point decrease) and current text warnings used in the United States (5.75 point decrease), although this difference was not statistically significant. Based on these pilot data, a larger study could further examine the effectiveness of graphic warning images and whether such warnings hold an advantage over the currently used text warnings.
- 1 December 2011
- Published by Cambridge University Press (CUP) in Journal of Smoking Cessation
- Vol. 6 (2) , 85-88
Evaluation of Graphic Cigarette Warning Images on Cravings to Smoke
While health warnings are present on cigarette packs around the world, the nature of the warnings varies considerably between countries. In the United States, a small text warning citing the dangers of cigarette smoking is found on the side of all packs. This pilot study sought to determine whether graphic cigarette warning images, like those found in the United Kingdom and Canada, were better at decreasing cravings to smoke than existing text warnings found on cigarette packs in the United States. Twenty-five smokers seeking treatment to quit at a specialty tobacco treatment program were administered the Brief Questionnaire of Smoking Urges (QSU — BRIEF), a validated measure of craving, prior to and following exposure to cigarette pack warning images. The graphic cigarette warning images reduced cravings to smoke (6.20 point decrease) more than neutral images (3.36 point decrease) and current text warnings used in the United States (5.75 point decrease), although this difference was not statistically significant. Based on these pilot data, a larger study could further examine the effectiveness of graphic warning images and whether such warnings hold an advantage over the currently used text warnings.
- 1 December 2011
- Published by Elsevier in Addictive Behaviors
- Vol. 36 (12) , 1127-1132
Tobacco dependence treatment for hospitalized smokers: A randomized, controlled, pilot trial using varenicline
- 1 December 2011
- Published by Elsevier in Addictive Behaviors
- Vol. 36 (12) , 1127-1132
Tobacco dependence treatment for hospitalized smokers: A randomized, controlled, pilot trial using varenicline
- 25 April 2011
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 12 (11) , 1799-1812
Varenicline for tobacco dependence: panacea or plight?
(2011). Varenicline for tobacco dependence: panacea or plight? Expert Opinion on Pharmacotherapy: Vol. 12, No. 11, pp. 1799-1812.
- 25 April 2011
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 12 (11) , 1799-1812
Varenicline for tobacco dependence: panacea or plight?
(2011). Varenicline for tobacco dependence: panacea or plight? Expert Opinion on Pharmacotherapy: Vol. 12, No. 11, pp. 1799-1812.
- 1 March 2011
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 114 (1) , 77-81
Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies
- 1 March 2011
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 114 (1) , 77-81
Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies
- 29 August 2010
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 4 (6) , 413-420
Smoking as a Chronic Disease
- 29 August 2010
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 4 (6) , 413-420
Smoking as a Chronic Disease
- 16 February 2010
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 152 (4) , 259-260
Tobacco Smoke by Any Other Name Is Still as Deadly
- 16 February 2010
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 152 (4) , 259-260
Tobacco Smoke by Any Other Name Is Still as Deadly
- 7 April 2009
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 150 (7) , 447-454
Triple-Combination Pharmacotherapy for Medically Ill Smokers
Smokers with medical illnesses are at particular risk for complications caused by tobacco. Clinical trial data on the effectiveness of triple-combination pharmacotherapy for tobacco dependence treatment in these high-risk smokers are not available. To evaluate extended duration of a triple-medication combination versus standard-duration therapy with the nicotine patch alone and 6-month abstinence rates in smokers with medical illnesses. Randomized clinical trial from 2005 to 2007. Single primary care setting. 127 smokers 18 years or older with predefined medical illnesses were recruited from the local community. Participants were allocated by blocked randomization to receive either the nicotine patch alone for a standard 10-week, tapering course (n = 64) or the combination of nicotine patch, nicotine oral inhaler, and bupropion ad libitum (n = 63). Nonstudy staff, who used computer-generated tables, assigned participants by telephone. No study staff had access to the randomization tables before randomization, thus maintaining concealment. Participants and study personnel were not blinded to treatment assignment. The primary outcome was 7-day, exhaled carbon monoxide-confirmed point abstinence at 26 weeks after target quit date. Secondary outcomes were the time to first relapse, duration of medication use, and adverse effects of medications. Analyses were conducted on an intention-to-treat basis with participants who were lost to follow-up (patch alone [n = 13] and combination therapy [n = 18]) classified as still smoking. Both treatment groups had similar baseline characteristics. Abstinence rates at 26 weeks were 35% (22 of 63 patients) for the combination group versus 19% (12 of 64 patients) for the patch-alone group (relapse benefit, 16% [95% CI, 1% to 31%]; P = 0.040). The adjusted odds ratio for abstinence in the combination group was 2.57 (CI, 1.05 to 6.32; P = 0.041). The median time to relapse was significantly longer in the combination group than in the patch-alone group (65 days vs. 23 days; P = 0.005). Some side effects occurred more frequently in the combination group (for example, insomnia [25% vs. 9%] and anxiety [22% vs. 3%]), but the proportion of participants who discontinued study medications because of adverse events was similar in both groups (6%). Approximately 25% of participants were lost to follow-up (proportions were similar between treatment groups). Treatment personnel and participants were unblinded. Flexibly dosed triple-combination pharmacotherapy for up to 6 months was more effective than standard-duration nicotine patch therapy for outpatient smokers with medical illnesses. Cancer Institute of New Jersey and Robert Wood Johnson Foundation.
- 7 April 2009
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 150 (7) , 447-454
Triple-Combination Pharmacotherapy for Medically Ill Smokers
Smokers with medical illnesses are at particular risk for complications caused by tobacco. Clinical trial data on the effectiveness of triple-combination pharmacotherapy for tobacco dependence treatment in these high-risk smokers are not available. To evaluate extended duration of a triple-medication combination versus standard-duration therapy with the nicotine patch alone and 6-month abstinence rates in smokers with medical illnesses. Randomized clinical trial from 2005 to 2007. Single primary care setting. 127 smokers 18 years or older with predefined medical illnesses were recruited from the local community. Participants were allocated by blocked randomization to receive either the nicotine patch alone for a standard 10-week, tapering course (n = 64) or the combination of nicotine patch, nicotine oral inhaler, and bupropion ad libitum (n = 63). Nonstudy staff, who used computer-generated tables, assigned participants by telephone. No study staff had access to the randomization tables before randomization, thus maintaining concealment. Participants and study personnel were not blinded to treatment assignment. The primary outcome was 7-day, exhaled carbon monoxide-confirmed point abstinence at 26 weeks after target quit date. Secondary outcomes were the time to first relapse, duration of medication use, and adverse effects of medications. Analyses were conducted on an intention-to-treat basis with participants who were lost to follow-up (patch alone [n = 13] and combination therapy [n = 18]) classified as still smoking. Both treatment groups had similar baseline characteristics. Abstinence rates at 26 weeks were 35% (22 of 63 patients) for the combination group versus 19% (12 of 64 patients) for the patch-alone group (relapse benefit, 16% [95% CI, 1% to 31%]; P = 0.040). The adjusted odds ratio for abstinence in the combination group was 2.57 (CI, 1.05 to 6.32; P = 0.041). The median time to relapse was significantly longer in the combination group than in the patch-alone group (65 days vs. 23 days; P = 0.005). Some side effects occurred more frequently in the combination group (for example, insomnia [25% vs. 9%] and anxiety [22% vs. 3%]), but the proportion of participants who discontinued study medications because of adverse events was similar in both groups (6%). Approximately 25% of participants were lost to follow-up (proportions were similar between treatment groups). Treatment personnel and participants were unblinded. Flexibly dosed triple-combination pharmacotherapy for up to 6 months was more effective than standard-duration nicotine patch therapy for outpatient smokers with medical illnesses. Cancer Institute of New Jersey and Robert Wood Johnson Foundation.
- 1 April 2008
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 148 (7) , 554-556
The Case for Treating Tobacco Dependence as a Chronic Disease
Smoking remains the leading cause of preventable death in the United States, yet it is still regarded by many as merely a bad habit. Most smokers want to quit but find it difficult. Behavioral counseling and pharmacotherapies are available, safe, and effective in the treatment of tobacco dependence. Nicotine replacement therapy effectively delivers nicotine in safer doses without exposure to the toxins and chemicals in cigarette smoke. The optimal duration of tobacco dependence treatment is unknown, and some smokers may require extended courses. For smokers using long-term cessation medications, health care providers should encourage treatment and insurance carriers should cover it. Both tobacco dependence and such conditions as diabetes are similar in their potential to exacerbate other diseases, their behavioral components of treatment, and their effectiveness of medications. Despite these similarities, treatments for diabetes are well covered by insurance, whereas tobacco dependence treatments are often limited. Tobacco dependence should share the status of other chronic illnesses, with effective treatments given as long as is necessary to achieve successful clinical outcomes.
- 1 April 2008
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 148 (7) , 554-556
The Case for Treating Tobacco Dependence as a Chronic Disease
Smoking remains the leading cause of preventable death in the United States, yet it is still regarded by many as merely a bad habit. Most smokers want to quit but find it difficult. Behavioral counseling and pharmacotherapies are available, safe, and effective in the treatment of tobacco dependence. Nicotine replacement therapy effectively delivers nicotine in safer doses without exposure to the toxins and chemicals in cigarette smoke. The optimal duration of tobacco dependence treatment is unknown, and some smokers may require extended courses. For smokers using long-term cessation medications, health care providers should encourage treatment and insurance carriers should cover it. Both tobacco dependence and such conditions as diabetes are similar in their potential to exacerbate other diseases, their behavioral components of treatment, and their effectiveness of medications. Despite these similarities, treatments for diabetes are well covered by insurance, whereas tobacco dependence treatments are often limited. Tobacco dependence should share the status of other chronic illnesses, with effective treatments given as long as is necessary to achieve successful clinical outcomes.